What’s New
Dear AsPEN members, Thanks very much for all your effort and support in making the AsPEN sustainable. We would like to show our appreciation to Kiyoshi and NPO DSUR Japan for the management and maintenance of AsPEN office. We specially thank our secretary, Yukari, for her wonderful organization and great assistance to make […]
The Prescription Sequence Symmetry Analysis (PSSA) Study 1: Association between antipsychotic use and diabetes. Objective: To test the feasibility of using a distributed model for undertaking studies in AsPEN. Design: A distributed network model was employed using fit for purpose code written by the University of South Australia to test the association between antipsychotic use […]
The Prescription Sequence Symmetry Analysis (PSSA) Study 2: Association between thiazolidinediones and cardiovascular diseases. Objective: To test the risk of cardiovascular disease from thiazolidinediones across AsPEN countries. Method: Pharmacogenetic differences between Asian and Caucasian populations led to a hypothesis that the adverse cardiovascular events of thiazolidinediones may be less common in Asian populations than Caucasian […]
The Prescription Sequence Symmetry Analysis (PSSA) Study 3: Prescription Symmetry: A validation study Objective: To test the validity of PSSA in identifying one positive and two negative controls across multiple data sets from different countries. Method: The positive control was amiodarone and thyroxine. Amiodarone is known to cause hypothyroidism. The negative controls were 1) amiodarone […]
The Prescription Sequence Symmetry Analysis (PSSA) Study 4: Association between proton pump inhibitor use and clostridium difficile infections Objective: To test the risk of treatment for clostridium difficile from proton pump inhibitors across AsPEN countries and Canada. Method: Health Canada had a hypothesis that proton pump inhibitors may contribute to clostridium difficile infections. Australia (two […]
